Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy - PubMed
5 hours ago
- #CAR-T therapy
- #multiple myeloma
- #BCMA expression
- BCMA expression at baseline is universal but heterogeneous in patients with relapsed/refractory multiple myeloma.
- High BCMA expression by flow cytometry correlates with better clinical outcomes, including deeper responses and longer time to progression.
- BCMA loss is rare at relapse, but decreased expression is common, with half of paired samples showing downregulation.
- Flow cytometry and immunohistochemistry show poor concordance in categorizing BCMA expression levels.
- Retained BCMA expression at relapse suggests potential for sequencing BCMA-directed therapies.